BioSante Pharmaceuticals Inc. said today it has been added to the broad-market Russell 3000 Index as part of Russell Investments’ recent reconstitution of its comprehensive set of U.S. and global equity indexes after market close Friday.

Russell reevaluates its U.S. indexes annually, capturing the 4,000 largest U.S. stocks, ranking them by total market capitalization. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

“We are delighted that BioSante has been included in the Russell 3000 Index, as it adds greater visibility for BioSante and potentially will lead to a broader stockholder base,” said Stephen M. Simes, president and chief executive officer.

BioSante is a pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel, for the treatment of female sexual dysfunction and Elestrin for the treatment of vasomotor symptoms associated with menopause. BioSante also is developing a portfolio of cancer vaccines.